Literature DB >> 25146774

Renal and hepatic integrity in long-term sevoflurane sedation using the anesthetic conserving device: a comparison with intravenous propofol sedation in an animal model.

L Gallego1, M Soro2, A Alvariño2, I Noguera3, F J Belda4.   

Abstract

INTRODUCTION: Critically ill patients are sedated with intravenous agents because the use of inhaled agents is limited by their potential risk of toxicity. Increasing levels of inorganic fluorides after the metabolism of these agents have been considered potentially nephrotoxic. However, hepatic involvement after prolonged administration of sevoflurane has not yet been studied. The present study evaluated the potential renal and hepatic toxicity caused by prolonged administration (72h) of sevoflurane.
METHODS: For this experimental, prospective, randomized, controlled trial, 22 Landrace x Large-White female pigs were randomly assigned to two groups: intravenous propofol (P) or inhaled sevoflurane via the AnaConDa™ device (S, end-tidal 2.5 vol%). The P group remained sedated for 108h with propofol. In the S group, sevoflurane was administered for 72h and then changed to propofol for the remaining 36h in order to observe the kinetics of fluoride after discontinuation of sevoflurane. Serum creatinine was the primary outcome variable, but inorganic fluoride concentrations and other renal, hepatic, and cardiorespiratory variables were also measured.
RESULTS: Both groups of animals were comparable at baseline. No differences were found between the two groups for plasma creatinine and urea or creatinine clearance throughout the study. Fluoride levels were significantly higher in the sevoflurane group. No correlation was found between inorganic fluoride and serum creatinine values. No significant differences were observed for hepatic function. Hemodynamic, respiratory, and blood gas variables were comparable between the groups.
CONCLUSIONS: Long-term sedation with sevoflurane using AnaConDa™ or propofol does not negatively affect renal or hepatic function.
Copyright © 2014 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  AnaConDa(®); AnaConDa™; Inhalational sedation; Renal toxicity; Sedación inhalatoria; Sevoflurane; Sevoflurano; Toxicidad renal

Mesh:

Substances:

Year:  2014        PMID: 25146774     DOI: 10.1016/j.redar.2014.05.009

Source DB:  PubMed          Journal:  Rev Esp Anestesiol Reanim        ISSN: 0034-9356


  1 in total

1.  Safety and Feasibility of AnaConDa™ to Deliver Inhaled Isoflurane for Sedation in Patients Undergoing Elective Postoperative Mechanical Ventilation: A Prospective, Open-label, Interventional Trial (INSTINCT I Study).

Authors:  Atul Prabhakar Kulkarni; Shilpushp Jagannath Bhosale; Kushal Rajeev Kalvit; Tarun Kumar Sahu; Rakesh Mohanty; Meshach M Dhas; Gautam Gondal; Swapna Charie; Anjana Shrivastava; Jigeeshu V Divatia
Journal:  Indian J Crit Care Med       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.